despite neutral imaging results, adalimumab did improve other key markers of inflammation in the blood including glyca, crp, tnf, and il-6..
..
eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention...
.. "the importance of our new method is that it allows for precise and automated measurement of the disease," bentley added in the study published in the journal radiology..